HHLA2 Vs PD-L1 Expression in Urothelial Tumors
September 1st 2016Alexander I. Sankin, MD, assistant professor of Urology at Montefiore Medical Center at the Albert Einstein College of Medicine, discusses the differences between the recently defined checkpoint HHLA2 and PD-L1 expression in urothelial tumors, as well as next steps in this space.
Watch
An Overview of the ALSYMPCA Study in Metastatic Prostate Cancer
September 1st 2016Luke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, gives an overview of the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) study, and he discusses ongoing trials examining the use of radium-223 dichloride (Xofigo) in metastatic castration-resistant prostate cancer (mCRPC).
Watch
The Investigation of Immune Checkpoint Blockades in Small Cell Lung Cancer
August 24th 2016Raffaele Califano, MD, consultant in medical oncology, The Christie Clinic, University Hospital of South Manchester, discusses the recent investigations into the use of immune checkpoint blockades in small cell lung cancer.
Watch